These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33022442)

  • 1. Depression and Buprenorphine Treatment in Patients with Non-cancer Pain and Prescription Opioid Dependence without Comorbid Substance Use Disorders.
    Scherrer JF; Salas J; Grucza R; Sullivan MD; Lustman PJ; Copeland LA; Ballantyne JC
    J Affect Disord; 2021 Jan; 278():563-569. PubMed ID: 33022442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buprenorphine/Naloxone dose and pain intensity among individuals initiating treatment for opioid use disorder.
    Becker WC; Ganoczy D; Fiellin DA; Bohnert AS
    J Subst Abuse Treat; 2015 Jan; 48(1):128-31. PubMed ID: 25312475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
    Worley MJ; Heinzerling KG; Shoptaw S; Ling W
    Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Emergency Department-Initiated Buprenorphine on Repeat Emergency Department Utilization.
    Skains RM; Reynolds L; Carlisle N; Heath S; Covington W; Hornbuckle K; Walter L
    West J Emerg Med; 2023 Nov; 24(6):1010-1017. PubMed ID: 38165181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
    Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
    J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Buprenorphine Dosage on the Occurrence of Relapses in Patients with Opioid Dependence.
    Reimer J; Vogelmann T; Trümper D; Scherbaum N
    Eur Addict Res; 2020; 26(2):77-84. PubMed ID: 31940657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Same-day vs. delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program.
    Jakubowski A; Lu T; DiRenno F; Jadow B; Giovanniello A; Nahvi S; Cunningham C; Fox A
    J Subst Abuse Treat; 2020 Dec; 119():108140. PubMed ID: 33138925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mobile, Community-Based Buprenorphine Treatment for Veterans Experiencing Homelessness With Opioid Use Disorder: A Pilot, Feasibility Study.
    Iheanacho T; Payne K; Tsai J
    Am J Addict; 2020 Nov; 29(6):485-491. PubMed ID: 32367557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does Prescription Length of Buprenorphine Influence Treatment Outcomes in Opioid Use Disorder? A Retrospective Cohort Study from North India.
    Ghosh A; Mahintamani T; Kathiravan S; Swer SB; Basu D; Mattoo SK; B N S; Singh A
    Subst Use Misuse; 2023; 58(12):1620-1624. PubMed ID: 37469041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short term health-related quality of life improvement during opioid agonist treatment.
    Nosyk B; Bray JW; Wittenberg E; Aden B; Eggman AA; Weiss RD; Potter J; Ang A; Hser YI; Ling W; Schackman BR
    Drug Alcohol Depend; 2015 Dec; 157():121-8. PubMed ID: 26511766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of buprenorphine initial outpatient maintenance and dose taper response among non-treatment-seeking heroin dependent volunteers.
    Woodcock EA; Lundahl LH; Greenwald MK
    Drug Alcohol Depend; 2015 Jan; 146():89-96. PubMed ID: 25479914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration.
    Kalluri HV; Zhang H; Caritis SN; Venkataramanan R
    Br J Clin Pharmacol; 2017 Nov; 83(11):2458-2473. PubMed ID: 28688108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome.
    Gerra G; Borella F; Zaimovic A; Moi G; Bussandri M; Bubici C; Bertacca S
    Drug Alcohol Depend; 2004 Jul; 75(1):37-45. PubMed ID: 15225887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buprenorphine alone or with naloxone: Which is safer?
    Kelty E; Cumming C; Troeung L; Hulse G
    J Psychopharmacol; 2018 Mar; 32(3):344-352. PubMed ID: 29433352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between opioid analgesic therapy and initiation of buprenorphine management: An analysis of prescription drug monitoring program data.
    Alexandridis AA; Dasgupta N; Ringwalt CL; Rosamond WD; Chelminski PR; Marshall SW
    PLoS One; 2020; 15(1):e0227350. PubMed ID: 31923197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.
    Greenwald MK; Comer SD; Fiellin DA
    Drug Alcohol Depend; 2014 Nov; 144():1-11. PubMed ID: 25179217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose transdermal buprenorphine - long-term use and co-medication with other potentially addictive drugs.
    Nordbø A; Skurtveit S; Borchgrevink PC; Kaasa S; Fredheim OM
    Acta Anaesthesiol Scand; 2012 Jan; 56(1):88-94. PubMed ID: 22092357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pain volatility and prescription opioid addiction treatment outcomes in patients with chronic pain.
    Worley MJ; Heinzerling KG; Shoptaw S; Ling W
    Exp Clin Psychopharmacol; 2015 Dec; 23(6):428-35. PubMed ID: 26302337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised Comparison of a Novel Buprenorphine Oral Lyophilisate versus Existing Buprenorphine Sublingual Tablets in Opioid-Dependent Patients: A First-in-Patient Phase II Randomised Open Label Safety Study.
    Strang J; Reed K; Bogdanowicz K; Bell J; van der Waal R; Keen J; Beavan P; Baillie S; Knight A
    Eur Addict Res; 2017; 23(2):61-70. PubMed ID: 28268215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant Heroin and Cocaine Use among Opioid-Dependent Patients during Methadone, Buprenorphine or Morphine Opioid Agonist Therapy.
    Gastberger S; Baumgartner MR; Soyka M; Quednow BB; Hulka LM; Herdener M; Seifritz E; Mutschler J
    Eur Addict Res; 2019; 25(4):207-212. PubMed ID: 31067528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.